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Heme oxygenase (HO) is a ubiquitous enzyme with various properties, but its main function is
catalyzing the rate-limiting step in heme degradation to produce equimolar quantities of biliverdin,
iron, and carbon monoxide (CO) (Tenhunen et al., 1968). Of its three isozymes, HO-2 and HO-3
are constitutively-expressed and HO-1 is inducible and acts as stress-response protein. It is not
only cytoprotective (Vile et al., 1994; Soares et al., 1998; Gozzelino et al., 2010); but also, exerts
anti-inflammatory effects (Otterbein et al., 2000, 2003; Soares and Bach, 2009). Together with its
modulatory effects on cell proliferation (Duckers et al., 2001; Lee and Chau, 2002), HO-1 can
prevent tissue injury. Also, HO-1 is known to regulate innate and adaptive immunity, and therefore
may prevent immune-mediated inflammatory diseases (Wagener et al., 2003; Soares and Bach,
2009; Soares et al., 2009). These effects can be inhibited pharmacologically and restored by CO
(Brouard et al., 2000; Otterbein et al., 2000; Lee and Chau, 2002; Ryter et al., 2002; Kim et al., 2006).
Pioneering work from the late Fritz Bach revealed the importance of HO-1 in organ
transplantation. Using wild-type (WT, Hmox1+/+) and Hmox1−/− mice, Soares et al. (1998)
demonstrated that the rapid expression of HO-1 by xenograft endothelial cells, smooth muscle
cells, and cardiac myocytes protects xenografts from rejection. The role of HO-1 in xenograft
and allograft acceptance is due to its cytoprotective properties that support cell survival and
function within the transplanted organ. Moreover, HO-1 can reduce the graft immunogenicity
by directly modulating recipient immune response such that regulatory responses are generated.
The activation of HO-1 expression in the graft and in immune cells of the recipient can prevent
rejection and promote immunotolerance, and probably due to the detoxification of free heme by
HO-1 (Soares and Bach, 2007).
Using a mouse model where tolerance is induced by donor-specific transfusion and anti-CD40L,
Yamashita et al. (2006) observed that HO-1 is necessary for long-term graft tolerance as grafts
do not survive in Hmox1−/− compared to WT control recipients. Modulation of HO-1 was
necessary to promote graft tolerance. Donor-specific transfusion alone failed to prolong survival
of transplanted hearts, but long-term survival and tolerance were achieved after HO-1 induction.
HO-1 induction plus donor-specific transfusion was associated with increases in regulatory T-cells
(Tregs) (Yamashita et al., 2006). The immunomodulatory effect on cells from graft recipients is
based on the fact that HO-1 directly modulates the phenotype of dendritic cells (DCs) (Moreau
et al., 2009). HO-1 is constitutively expressed in immature DCs; however, its expression decreases
during DC maturation. HO-1 upregulation can maintain DCs in an immature state, which
suppresses the immune response, and then leads to antigen-specific Treg generation (George et al.,
2008; Schumacher et al., 2012). Because Tregs from Hmox1−/− mice are functional, it can be
concluded that the suppressive function of Tregs depends upon HO-1-induced modulation of DCs
rather than HO-1 expression by Tregs (Zelenay et al., 2007).
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In the article by Schumacher and Zenclussen (2015), the
participation of HO-1 in immunomodulation during pregnancy
and organ transplantation is discussed. They report how HO-
1 promotes alloantigen tolerance by blocking DC maturation
reduces T-cell responses and increases Treg numbers. Further
mechanisms involve the cytokine milieu, tissue protection,
and apoptosis. Hence, HO-1 can mediate acceptance of a
transplanted allogeneic graft through organ cytoprotection and
immunotolerance. A similar scenario may be true for a growing
fetus, which is semi-allogeneic to the mother, where HO-1
confers both semi-allograft cytoprotection and immunotolerance
in the maternal immune system.
Because of its role in the modulation of innate and
adaptive immune responses, HO-1 is linked to carcinogenesis by
influencing tumor induction, growth, and metastasis (Jozkowicz
et al., 2007). HO-1 is highly expressed in several tumors, and
accordingly, inhibition of HOmay have potential as a therapeutic
approach. Because tumors are highly vascularized and prone
to massive hemorrhaging, large quantities of free heme can be
released, and induce HO-1 that in turn negatively influences
the host and protects the tumor from oxidative injury. HO-1
is also involved in tumor angiogenesis and stimulating tumor-
associatedmacrophages (Was et al., 2010), and thus, may regulate
tumor survival and progression.
Zhao et al. (2015) discuss how HO-1 regulates similar
processes in transplantation and pregnancy, particularly in
invasion and neovascularization. Pregnancy is a physiological
state characterized by interactions of various processes occurring
at different stages. For these changes to occur, tissue and vascular
remodeling as well as both pro- and anti-inflammatory processes
in the uterus are required. However, once the placenta has
formed and the fetus grows, the fetoplacental unit behaves more
like a graft that is tolerated by its host. When pregnancy is
near completion, the semi-allograft is naturally “rejected” by the
mother resulting in birth.
Zenclussen et al. (2015) review how HO-1 impacts
reproductive processes, highlighting its importance in placental
function and fetal development. The deletion of Hmox1 in mice
leads to inadequate spiral artery remodeling and suboptimal
placentation followed by intrauterine growth restriction and
fetal death (Zhao et al., 2009; Zenclussen et al., 2011). A
partial Hmox1 deletion is compatible with pregnancy, however
heterozygote females develop gestational hypertension (Linzke
et al., 2014). The protective effects of HO-1 on placentation and
fetal growth can be mimicked by exogenous administration of
CO. CO promotes the in situ proliferation of uterine natural
killer (uNK) cells, restores placentation, and fetal growth, while
normalizing blood pressure (Linzke et al., 2014). Similarly, HO-1
inhibition provokes hypertension in pregnant rats (George et al.,
2013).
The relevance of HO-1 in the regulation of immune responses
during pregnancy is further highlighted in the article by George
et al. (2015). They investigated whether HO-1 induction could
attenuate TNF-α-induced hypertension in pregnancy. HO-1
induction significantly decreased blood pressure in TNF-α-
infused animals, which was accompanied by a normalization of
vascular parameters, supporting the notion that HO-1 is essential
in counteracting the negative effects of excessive inflammation.
In summary, the HO-1/CO axis may play a pivotal role in
sustaining pregnancy, and thus understanding its biology during
pregnancy may reveal promising therapeutic approaches for
pregnancy complications.
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